|
The purpose of this guidance is to help UC Berkeley investigators determine in which cases they may rely on another UC IRB (Institutional Review Board) to review their human research projects. Current UCB policy requires that all faculty, staff, and students (as applicable) must have approval from UCB’s IRB, the CPHS (Committee for Protection of Human Subjects) before they begin research using human subjects. This requirement applies regardless of the source of funding and even when no funds are involved, and regardless of the site of the study activities. However, there are several exceptions, which are described below. The following limited exceptions have been made in response to requests by investigators for a more streamlined IRB review for research studies involving multiple UC campuses. |
Definitions and Responsibilities Reviewing IRB
Relying IRB
|
Memorandum of Understanding (MOU) Between Human Research Protection Programs at University of California Campuses and UC-Managed Laboratories for IRB Review of Multi-Campus Human Subject Research for Exempt and Expedited Categories of Research This Memorandum of Understanding (MOU) applies to research eligible for expedited review research involving no more than minimal risk to the subject, as well as research that qualifies for exempt status review. When applicable, the MOU will allow research to be reviewed by the IRB at only one UC location rather than having to go through the entire IRB process at every UC campus at which the research will take place. The MOU became effective March 21, 2006. Click on Memorandum of Understanding Between Human Research Protection Programs at University of California Campuses and UC-Managed Laboratories for IRB Review of Multi-Campus Human Subject Research to see the MOU in its entirety. Conditions of Use: A Lead Investigator (LI) from UC Berkeley may request that another UC IRB review his or her application if: 1) The research is not regulated by the FDA; and, 2) Any of the following conditions are met:
Steps for Use:
|